Alcidion Lands $35M NHS Contract for Third UK Hospital Record Platform Win

By Josua Ferreira -

Alcidion lands third UK EPR contract with $35M UHSussex deal

Alcidion Group Limited (ASX: ALC) has signed a seven-year contract with University Hospitals Sussex NHS Foundation Trust (UHSussex) to deploy its Miya Precision Electronic Patient Record (EPR) platform. The deal carries a total contract value (TCV) of approximately $35M, with extension rights to 10 years and a potential TCV of $49M. Alcidion expects to recognise approximately $8.5M in revenue during FY26, making this the company’s third EPR platform contract win in the UK, secured through a competitive tender process.

What is an Electronic Patient Record, and why does this contract matter?

An EPR platform is a unified digital system that gives clinicians real-time access to patient information across an entire healthcare organisation. It replaces fragmented, paper-based, and legacy systems with a single integrated record that supports clinical decision-making, operational efficiency, and care coordination.

NHS trusts across the United Kingdom are investing heavily in EPR platforms as part of a broader government-backed digital transformation programme. The push to modernise hospital infrastructure is driven by the need to reduce clinical errors, improve patient outcomes, and create interoperability across regional care networks. For healthcare technology vendors, this creates a large and structurally supported procurement pipeline.

UHSussex is one of the UK’s largest acute trusts. It provides hospital and community healthcare for approximately one million people in Sussex from seven hospitals, hosting more than 1.5 million outpatient appointments, A&E visits, and surgery cases annually. The trust employs nearly 20,000 staff and forms part of the Surrey and Sussex Integrated Care Board (ICB).

Winning competitive tenders of this scale is significant for several reasons. Contracts span multiple years, generating predictable long-term revenue. Large trusts also provide a platform for progressive module expansion, meaning the initial contract value rarely represents the ceiling of the commercial relationship.

Miya Precision’s modular advantage

Alcidion is building on an existing relationship at UHSussex, where its Patientrack solution (Miya Observations and Assessments) is already live. The new deployment broadens the scope considerably, adding virtual care, remote patient monitoring, streamlined patient flow, and clinical decision support capabilities.

The virtual care module is of particular note: this marks the first time Alcidion will deploy this module to a UK customer, opening a new expansion pathway across its broader NHS client base. The contract also includes options for additional modules over time, specifically Miya Emergency and a Patient Administration System (PAS), which would increase TCV beyond the current $49M ceiling if exercised.

Contract financials and timeline

The financial structure of the UHSussex agreement reflects both immediate and long-term revenue potential. The majority of FY26 revenue recognition of approximately $8.5M is driven by an upfront licence fee for use of the platform over the seven-year term.

One important distinction: there is an outgoing upfront payment of approximately $2M to a third party for the medications management module. This is a cost to Alcidion, not revenue, and should be understood separately from the contract’s revenue contribution.

Implementation begins immediately and is expected to take approximately 18 months, with a phase one go-live target of June 2027.

Metric Detail
Contract term 7 years (extendable to 10 years)
TCV (initial term) ~$35M
TCV (if extended) ~$49M
FY26 revenue recognition ~$8.5M
Phase 1 go-live target June 2027

Kate Quirke, Managing Director, Alcidion

“The modular nature of our Miya Precision platform will result in UHSussex being able to realise the benefits of an EPR platform deployment progressively, helping to maximise the ROI for clinicians and patients alike.”

Roxanne Smith, Chief Strategy Officer, University Hospitals Sussex

“This is an important milestone in our long-term digital strategy and a significant step towards introducing an Electronic Patient Record at UHSussex.”

What this means for Alcidion’s UK revenue pipeline

This contract reinforces a repeatable commercial pattern. Alcidion’s existing Patientrack deployment at UHSussex reduced competitive risk during the tender process and validates the company’s land-and-expand model, where an initial module deployment creates a foundation for broader platform adoption over time.

The first UK deployment of the virtual care module is strategically significant. If it performs well at UHSussex, it creates a reference site that could support uptake across Alcidion’s existing NHS customer base.

Key investment takeaways from the announcement include:

  • Third UK EPR contract win, demonstrating repeatable traction in the NHS market
  • Virtual care module deployed in the UK for the first time, opening a new expansion pathway
  • Optional modules (Miya Emergency and PAS) provide further TCV upside beyond $49M
  • 18-month implementation with progressive go-live milestones, beginning immediately

Building a scalable NHS footprint

Alcidion now serves more than 400 hospitals and 87 healthcare organisations across the UK, Australia, and New Zealand. The UHSussex contract adds another anchor relationship to a growing NHS portfolio and demonstrates the company’s ability to compete and win in large, structured procurement processes.

The broader NHS digital transformation programme provides a structural tailwind that extends well beyond any single contract. As the UK government continues to prioritise EPR adoption across acute trusts, vendors with proven platforms and existing deployments are well positioned to benefit from successive procurement cycles.

With implementation now underway, a phase one go-live target of June 2027, and module expansion optionality remaining on the table, the UHSussex contract keeps Alcidion’s UK growth narrative active across multiple time horizons.

Don’t Miss the Next Healthcare Tech Winner on ASX

Big News Blast delivers FREE breaking ASX healthcare and tech news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts now.


Frequently Asked Questions

What is the Alcidion Miya Precision EPR platform?

Miya Precision is Alcidion's Electronic Patient Record platform that provides clinicians with real-time, unified access to patient information across an entire healthcare organisation, replacing fragmented legacy systems with integrated clinical decision support and care coordination capabilities.

What is the total value of the Alcidion UHSussex contract?

The contract has an initial total contract value of approximately $35M over seven years, with extension rights to 10 years that would bring the potential TCV to approximately $49M, plus further upside if optional modules such as Miya Emergency and a Patient Administration System are exercised.

How much revenue will Alcidion recognise from the UHSussex deal in FY26?

Alcidion expects to recognise approximately $8.5M in revenue during FY26, with the majority driven by an upfront licence fee for use of the Miya Precision platform over the seven-year contract term.

When will the Alcidion UHSussex EPR deployment go live?

Implementation began immediately following the contract signing, with a phase one go-live target of June 2027 following an approximately 18-month implementation period.

How does this contract fit into Alcidion's broader NHS strategy?

The UHSussex deal is Alcidion's third UK EPR contract win and builds on an existing Patientrack deployment at the trust, reinforcing the company's land-and-expand model across an NHS customer base that now spans more than 87 healthcare organisations in the UK.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher